Come and visit us at Respiratory Professional Care – 12th and 13th October 2022, NEC Birmingham
Register here… Read More
ALTURiX Commits To The NHS Net Zero Roadmap
The global health sector accounts for around 4% of emissions worldwide. That’s more than shipping or aviation. The NHS carbon footprint totals 25 million tonnes per… Read More
Press Release: ALTURiX Acquires UK Rights to Liothyronine
Issued: London, Monday 30th May 2022 Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has acquired the exclusive rights to liothyronine for the United… Read More
Press Release: ALTURiX Acquires UK and Ireland Rights to Metolazone
Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has acquired the rights to metolazone for the United Kingdom and the Republic of Ireland… Read More
ALTURiX Launch The Medicines Value Programme
ALTURiX was formed with the vision of helping to change things. Its five Founders are all driven by the desire to make a difference to the… Read More
ALTURiX Sponsor Bedfordshire County Cricket Club
ALTURiX are delighted to announce their support for Bedfordshire County Cricket Club for the forthcoming 2022 season. As the Club’s main sponsor, we are very… Read More
NACSYS® Hospital Tenders Awarded
ALTURiX Ltd are pleased to announce that NACSYS has been awarded hospital contract supplier status for acetylcysteine 600mg effervescent tablets (DHF 021) for CESW (CCM/PHG/17/5532/02), LSNE (CM/PHG/17/5532/02) and NWLN (CM/PHG/17/5532/02). These tenders… Read More
We’re Recruiting! QP and Quality Manager
We are looking for a talented QP and Quality Manager to join our awesome team. Click here for a copy… Read More
CEYESTO® Hospital Tenders Awarded
ALTURiX Ltd are pleased to announce that CEYESTO Melatonin 3mg tablets have been recently awarded contracts for DLD014 Melatonin Tablets 3mg Pack/30 for the CESW and… Read More
CEYESTO Launch: November 1st
ALTURiX Ltd are pleased to announce the launch of CEYESTO® Melatonin 3mg tablets. An additional option in the treatment of adult jet lag is… Read More
ALTURiX Supports US Cambridge Health Alliance Harvard Study
ALTURiX is pleased to announce its support for the NACinCOVID Study which is being coordinated by the Cambridge Health Alliance (CHA) based in Cambridge, Massachusetts. Read More
All Products Back In Stock At Movianto
Issued: 12th October 2020, Milton Keynes. Following a period of unpredictable growth in product demand, ALTURiX is aware that recently local… Read More
ALTURiX Acquires Slow-K® UK Rights
ALTURiX is pleased to announce that it has acquired the UK rights to Slow-K® from Alliance Pharmaceuticals. Alliance withdrew Slow-K® from the market in late… Read More
May COVID-19 Update
The world continues to face the challenges of the global threat from COVID-19, and we at ALTURiX continue to do everything we can to play… Read More
COVID-19 Update
The ALTURiX mission is to provide medicines value, and to do so reliably to help the NHS improve patient outcomes. Never has this been more… Read More
